Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q1fy2026roivantearningsrel.htm EX-99.1 Document Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update • Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track fo
Venker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $34.95 ($6.99M total) on 2026-07-27 under a Rule 10b5-1 trading plan.
Arbutus Biopharma (ABUS) and Genevant Sciences, a Roivant unit, filed three international patent lawsuits against Pfizer and BioNTech to enforce LNP patents tied to mRNA-LNP COVID-19 vaccines, seeking monetary relief and injunctions. Arbutus said it received about $178 million from Moderna under a settlement and expects a Genevant-parent dividend in Q3 2026, plus share repurchases up to about $230 million starting Q3 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning ROIV (Roivant Sciences Ltd.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ROIV coverage spans insider activity, earnings and financial news.
In the last 30 days, ROIV insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($7.0M). The most active reporter was Venker Eric, President & Immunovant CEO, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Near-term trading focus is on the credibility of clinical timelines and cash runway into profitability, plus the Moderna settlement cash inflow.
This is a routine, pre-planned insider sale with disclosed size and price, offering limited incremental signal beyond positioning/liquidity.
ROIV is indirectly exposed through its Genevant unit, but the article provides no ROIV-specific financial terms beyond the dividend expectation.
Routine director 10b5-1 sale; modest near-term sentiment impact at most, with limited fundamental signal.
Insider selling by a director can modestly affect sentiment, but this is not a new fundamental catalyst by itself.
alphai scores every news story that mentions ROIV with an AI model for sentiment and relevance, and aggregates insider trades from Roivant Sciences Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Roivant Sciences Ltd. (ROIV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q1fy2026roivantearningsrel.htm EX-99.1 Document Exhibit 99.1 Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update • Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track fo
6 min readVenker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $34.95 ($6.99M total) on 2026-07-27 under a Rule 10b5-1 trading plan.
1 min readArbutus Biopharma (ABUS) and Genevant Sciences, a Roivant unit, filed three international patent lawsuits against Pfizer and BioNTech to enforce LNP patents tied to mRNA-LNP COVID-19 vaccines, seeking monetary relief and injunctions. Arbutus said it received about $178 million from Moderna under a settlement and expects a Genevant-parent dividend in Q3 2026, plus share repurchases up to about $230 million starting Q3 2026.
4 min readEpperly Melissa B, sold 17,750 shares of Roivant Sciences Ltd. (ROIV) at an average of $34.38 ($34.32–$34.71, $0.61M total) across 2 trades on 2026-06-29 under a Rule 10b5-1 trading plan.
2 min readMANCHESTER KEITH S sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at $35.45 ($7.09M total) on 2026-06-30.
2 min readMANCHESTER KEITH S sold 1,438,163 indirectly-held shares of Roivant Sciences Ltd. (ROIV) at an average of $34.32 ($33.92–$35.28, $49.35M total) across 5 trades over 2026-06-26 to 2026-06-30.
2 min readGold Daniel Allen sold 1,438,163 indirectly-held shares of Roivant Sciences Ltd. (ROIV) at an average of $34.32 ($33.92–$35.28, $49.35M total) across 5 trades over 2026-06-26 to 2026-06-30.
2 min readQVT Financial LP sold 1,438,163 indirectly-held shares of Roivant Sciences Ltd. (ROIV) at an average of $34.32 ($33.92–$35.28, $49.35M total) across 5 trades over 2026-06-26 to 2026-06-30.
4 min readSukhatme Mayukh (President & CIO) sold 1,000,000 shares of Roivant Sciences Ltd. (ROIV) at an average of $34.10 ($34.08–$34.13, $34.10M total) across 2 trades over 2026-06-25 to 2026-06-26.
2 min readVenker Eric (President & Immunovant CEO) sold 200,000 shares of Roivant Sciences Ltd. (ROIV) at an average of $33.16 ($33.05–$33.51, $6.63M total) across 2 trades on 2026-06-24 under a Rule 10b5-1 trading plan.
2 min read
